Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes
暂无分享,去创建一个
F. Rubino | P. Schauer | W. Oh | H. Gerstein | Roy Taylor | W. Cefalu | M. Riddle | C. L. le Roux | M. Nauck | A. Rothberg | D. Twenefour | P. H. Evans | P. Evans | Douglas Twenefour
[1] F. Rubino,et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial , 2021, The Lancet.
[2] W. Herman,et al. Metformin Should Be Used to Treat Prediabetes in Selected Individuals , 2020, Diabetes Care.
[3] M. Davidson. Metformin Should Not Be Used to Treat Prediabetes , 2020, Diabetes Care.
[4] K. Khunti,et al. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis , 2020, BMJ.
[5] W. Ming,et al. Incidence Rate of Type 2 Diabetes Mellitus after Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of 170,139 Women , 2020, Journal of diabetes research.
[6] Roy Taylor,et al. Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS) , 2019, British Journal of Diabetes.
[7] Angela M Rodrigues,et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. , 2019, The lancet. Diabetes & endocrinology.
[8] R. Beck,et al. Continuous Glucose Monitoring Profiles in Healthy Non-Diabetic Participants: A Multicenter Prospective Study. , 2019, The Journal of clinical endocrinology and metabolism.
[9] Benjamin S. Aribisala,et al. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. , 2018, Cell metabolism.
[10] Benjamin S. Aribisala,et al. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. , 2018, Cell metabolism.
[11] R. Beck,et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring , 2018, Diabetes Care.
[12] Thomas P. Smith,et al. EurA1c: The European HbA1c Trial to Investigate the Performance of HbA1c Assays in 2166 Laboratories across 17 Countries and 24 Manufacturers by Use of the IFCC Model for Quality Targets. , 2018, Clinical chemistry.
[13] Eyal Dassau,et al. International Consensus on Use of Continuous Glucose Monitoring , 2017, Diabetes Care.
[14] R. Beck,et al. The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading , 2017, Diabetes Care.
[15] H. Gerstein,et al. Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial , 2017, The Journal of clinical endocrinology and metabolism.
[16] Deepak L. Bhatt,et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5‐Year Outcomes , 2017, The New England journal of medicine.
[17] W. Herman,et al. Reconciliation of Type 2 Diabetes Remission Rates in Studies of Roux-en-Y Gastric Bypass , 2016, Diabetes Care.
[18] Roy Taylor,et al. Type 2 Diabetes: The Pathologic Basis of Reversible β-Cell Dysfunction , 2016, Diabetes Care.
[19] F. Rubino,et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. , 2016, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.
[20] B. Zinman,et al. Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes , 2016, BMJ Open Diabetes Research and Care.
[21] F. Rubino,et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations , 2016, Diabetes Care.
[22] A. MacCormick,et al. Progression of diabetic retinopathy after bariatric surgery , 2015, Diabetic medicine : a journal of the British Diabetic Association.
[23] Deepak L. Bhatt,et al. Effect of Bariatric Surgery Versus Intensive Medical Management on Diabetic Ophthalmic Outcomes , 2015, Diabetes Care.
[24] B. Zinman,et al. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. , 2013, The lancet. Diabetes & endocrinology.
[25] R. Wing,et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. , 2012, JAMA.
[26] A. Ceriello. The emerging challenge in diabetes: the "metabolic memory". , 2012, Vascular pharmacology.
[27] D. Yue,et al. Steroid-Induced Diabetes: Is It Just Unmasking of Type 2 Diabetes? , 2012, ISRN endocrinology.
[28] Benjamin S. Aribisala,et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol , 2011, Diabetologia.
[29] C. Fox,et al. Low Hemoglobin A1c and Risk of All-Cause Mortality Among US Adults Without Diabetes , 2010, Circulation. Cardiovascular quality and outcomes.
[30] R. Klein,et al. Glycated Hemoglobin and the Risk of Kidney Disease and Retinopathy in Adults With and Without Diabetes , 2010, Diabetes.
[31] R. Heine,et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study , 2010, The Lancet.
[32] Sonia Caprio,et al. How Do We Define Cure of Diabetes? , 2009, Diabetes Care.
[33] E. Barnes. Between remission and cure: patients, practitioners and the transformation of leukaemia in the late twentieth century , 2007, Chronic illness.
[34] G. Treviño. Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation , 2007, Diabetes Care.
[35] Mathias M. Müller,et al. Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement , 2007, Diabetes Care.
[36] E. Ferrannini,et al. Beta-cell function in severely obese type 2 diabetic patients: long-term effects of bariatric surgery. , 2007, Diabetes care.
[37] M. Panteghini,et al. The importance of metrological traceability on the validity of creatinine measurement as an index of renal function: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) , 2006, Clinical chemistry and laboratory medicine.
[38] R. Taylor,et al. Long-term progression of retinopathy after initiation of insulin therapy in Type 2 diabetes: an observational study , 2004, Diabetologia.
[39] R. Paroni,et al. Approved IFCC Reference Method for the Measurement of HbA1c in Human Blood , 2002, Clinical chemistry and laboratory medicine.
[40] B. Davies,et al. European Association for the Study of Diabetes , 1984 .
[41] C. Fox,et al. Low Hemoglobin A 1 c and Risk of All-Cause Mortality Among US Adults Without Diabetes April , 2010 .
[42] Consensus Committee. Consensus statement on the worldwide standardisation of the HbA1c measurement , 2007, Diabetologia.
[43] S. Inzucchi,et al. Metformin: new understandings, new uses. , 2003, Drugs.
[44] G. Striker. Glucose toxicity. , 2001, Kidney international.
[45] Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. , 1998, Archives of ophthalmology.